A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting

2025-521919-39-00 Protocol CJPB898A12101 Human pharmacology (Phase I) - Other Authorised, recruiting

Start 10 Feb 2026 · Status Authorised, recruiting · 4 EU/EEA countries · 30 sites · Protocol CJPB898A12101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruiting
Participants planned 156
Countries 4
Sites 30

Resected stage IIB, IIC, or III melanoma requiring adjuvant treatment

Key facts

Sponsor
H e x a l AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
10 Feb 2026 → ongoing
Decision date (initial)
2026-05-07
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Resected stage IIB, IIC, or III melanoma requiring adjuvant treatment

VersionLevelCodeTermSystem organ class
21.1 PT 10025650 Malignant melanoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

H e x a l AG

Sponsor organisation
H e x a l AG
Address
Industriestrasse 25
City
Holzkirchen
Postcode
83607
Country
Germany

Scientific contact point

Organisation
H e x a l AG
Contact name
Biosimilar Clinical Trials Information Point

Public contact point

Organisation
H e x a l AG
Contact name
Biosimilar Clinical Trials Information Point

Locations

4 EU/EEA countries · 30 investigational sites

By country

CountryMS statusPlanned subjectsSites
Greece Authorised, recruitment pending 6 3
Italy Authorised, recruiting 8 4
Romania Authorised, recruiting 15 1
Spain Ongoing, recruiting 54 22
Rest of world
Moldova, Republic of, Georgia, India
73

Investigational sites

Greece

3 sites · Authorised, recruitment pending
St. Luke's Hospital S.A.
Oncology Department, Harilaou Trikoupi Str. 3, 552 36, Thessaloniki
Athens Medical Center S.A.
Oncology Department, Pylea, Asklipiou 10, Thessaloniki
Theageneio Cancer Hospital
Oncology Department, Simeonidi Alex 2, 546 39, Thessaloniki

Italy

4 sites · Authorised, recruiting
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
U.O. Oncologia, Piazzale Spedali Civili 1, 25123, Brescia
Azienda Unita Sanitaria Locale Della Romagna
U.O. Oncologia, Dipartimento Onco-Ematologico, Viale Vincenzo Randi 5, 48121, Ravenna
Azienda Ospedaliero Universitaria Delle Marche
Dipartimento Di Medicina Interna – Sod Clinica Oncologica, Via Conca 71, 60126, Ancona
Azienda Ospedaliero-Universitaria Senese
Uoc Immunoterapia Oncologica, Viale Mario Bracci 2, 53100, Siena

Romania

1 site · Authorised, recruiting
Centrul De Oncologie SF Nectarie S.R.L.
Oncology, Strada Caracal Nr 109, 200542, Craiova

Spain

22 sites · Ongoing, recruiting
Hospital San Pedro De Alcantara
Oncologia Medica, Avenida De Pablo Naranjo Porras S/n, 10002, Caceres
Hospital Universitario 12 De Octubre
Oncologia Medica, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitario De Badajoz
Oncologia Medica, Avenida Elvas S/n, 06006, Badajoz
Hospital De La Santa Creu I Sant Pau
Oncologia Medica, Carrer De San Quinti 89, 08041, Barcelona
Hospital Universitario De Torrejon
Oncologia Medica, Calle De Mateo Inurria 1, 28850, Torrejon De Ardoz
Hospital Clinic De Barcelona
Oncologia Medica, Calle Villarroel 170, 08036, Barcelona
Complejo Hospitalario Universitario Insular Materno Infantil
Oncologia Medica, Autovia Del Sur S/n, 35017, Las Palmas De Gran Canaria
Hospital Universitario Regional De Malaga
Oncologia Medica, Avenida De Carlos De Haya S/N, 29010, Malaga
Hospital Universitario Marques De Valdecilla
Oncologia Medica, Avenida Valdecilla Sn, 39008, Santander
Micancer Center S.L.P.
Oncologia Medica, Avinguda De Prat De La Riba 79, 25004, Lleida
Hospital Universitario De Canarias
Oncologia Medica, Carretera Ofra S/N, 38320, San Cristobal De La Laguna
Hospital Jerez Puerta Del Sur Grupo Hla S.A.
Oncologia Medica, Avenida De La Puerta Del Sur Sn, 11408, Jerez De La Frontera
Fundacion Instituto Valenciano De Oncologia
Oncologia Medica, Calle Professor Beltran Baguena 8, 46009, Valencia
MD Anderson Cancer Center
Oncologia Medica, Calle De Arturo Soria Nº 270, 28033, Madrid
Hospital Beata Maria Ana
Oncologia Medica, Calle Del Doctor Esquerdo No. 83, 28007, Madrid
Hospital Universitari Dexeus Grupo Quironsalud
Oncologia Medica, Calle De Sabino Arana 5-19, 08028, Barcelona
Hospital Universitario Central De Asturias
Oncologia Medica, Avenida De Roma S/n, 33011, Oviedo
Parc Tauli Hospital Universitari
Oncologia Medica, Parc Del Tauli 1, 08208, Sabadell
Hospital Universitario Quironsalud Madrid
Oncologia Medica, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
University Hospital Virgen Del Rocio S.L.
Oncologia Medica, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Universitario Clinico San Cecilio
Oncologia Medica, Avenida Del Conocimiento S/n, Poligono Industrial De Ciencias De La Salud, Granada
Hospital Universitario Puerta De Hierro De Majadahonda
Oncologia Medica, Calle De Joaquin Rodrigo 2, 28222, Majadahonda

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2026-05-05
Romania 2026-03-13
Spain 2026-02-10 2026-02-18

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-09-19 Spain Acceptable
2026-01-26
2026-01-27
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-03-17 Spain Acceptable
2026-01-26
2026-03-17
3 SUBSEQUENT ADDITION OF MSC APP-3 2026-03-26 Acceptable
2026-01-26
2026-05-07
4 SUBSTANTIAL MODIFICATION SM-1 2026-04-17 Spain Acceptable 2026-05-25